Amneal rolls out Crexont
Amneal is releasing Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease.
Crexont is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets. It is now broadly available at United States pharmacies.
“We are pleased to launch Crexont and make it broadly available to healthcare providers and patients. The product’s innovative formulation provides a longer duration of 'Good On' time with less frequent dosing compared to immediate release CD/LD. As a leader in the Parkinson’s space, Amneal has a long history of working closely with movement disorder specialists and neurologists. We are excited to build on this foundation with the rollout of a comprehensive education program and extensive services to help healthcare providers and patients access this innovative therapy,” said Joe Renda, senior vice president, chief commercial officer – specialty.
[Related: Amneal touts 39 retail, injectable product launches in 2023]
Eligible commercially insured patients may qualify for a $25 copay on their prescriptions, applied automatically for most patients at the pharmacy through the Crexont Savings Program.
Eligible patients will be able to have their Crexont prescriptions covered through the Amneal Patient Assistance Program.
[Read more: Amneal touts 26 generic new product launches in 2022]